Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509873 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 578
- Enrollment target
NCT00509873: Completed Phase 3 study, sponsored by Allergan.
NCT00509873 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 578 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509873, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 578 participants
- Enrollment target
Study Summary
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
Primary Outcome
Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).
Interventions
- DRUG placebo eye drops
- DRUG Gatifloxacin 0.5% eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 578 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00509873 record still lists
NCT00509873 is an interventional study that assigns participants to a tested intervention. The registered 578 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo eye drops is the first listed.
NCT00509873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00509873 about?
NCT00509873 is a clinical study titled "A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis". The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
What is the current status of trial NCT00509873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 578 participants. The study started on 2007-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00509873?
The interventions under investigation include: placebo eye drops (DRUG), Gatifloxacin 0.5% eye drops (DRUG).
Who is sponsoring clinical trial NCT00509873?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00509873's enrollment target sits among peer trials
578 661st of 2000 higher than 1,340 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07290543 · 578 participants · NA
Web-Based Toolkit to Improve Cancer-Related Emotional Distress and Anxiety in Rural Older Cancer Survivors
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia